News Release

Results from the COAPT trial reported at TCT 2018 and published simultaneously in NEJM

Transcatheter device used to treat secondary mitral valve regurgitation in heart failure patients reduces hospitalizations, enhances quality of life, and improves survival

Peer-Reviewed Publication

Cardiovascular Research Foundation

SAN DIEGO - September 23, 2018 - Data presented today from the randomized COAPT trial, which have the potential to significantly change current clinical practice, found that patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally tolerated medical therapy demonstrated reduced rates of hospitalizations and death, as well as improved quality-of-life and functional capacity after being treated with the transcatheter MitraClip device.

Findings were reported today at the 30th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. The study was also published simultaneously in the New England Journal of Medicine.

"The prognosis for heart failure patients who develop severe secondary mitral regurgitation is poor with limited treatment options," said Gregg W. Stone, MD, Professor of Medicine at Columbia University Irving Medical Center, and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Irving Medical Center, who presented the results at TCT. "There is a great need to help improve outcomes for these very sick patients."

The MitraClip device is already approved in the U.S. for use in primary MR, a condition in which the mitral valve leaflets do not function properly due to a degenerative defect.

Whether the device is useful for secondary MR, in which the valve structure is normal, but the ventricle is enlarged, causing the valve leaflets to fail to prevent backward flow (known as mitral regurgitation), is unknown. In the procedure tested in COAPT for secondary MR, the MitraClip device is attached to the mitral valve leaflets via a catheter that is then removed, leaving the clipped valve in place with less regurgitation.

COAPT was a randomized, parallel-controlled, open-label multicenter trial evaluating transcatheter mitral valve repair with the MitraClip device in symptomatic heart failure patients with moderate-to-severe or severe secondary MR. A total of 614 subjects were randomized at 78 centers in the United States and Canada. A total of 302 patients were assigned to the device and guideline-directed medical therapy (GDMT) in the device group and 312 patients were assigned to GDMT alone in the control group.

The primary effectiveness endpoint was the annualized rate of all heart failure hospitalizations through 24 months and the primary safety endpoint was freedom from device-related complications at 12 months. After two years, there were 160 total heart failure hospitalizations among those who received the mitral clip versus 283 for the control group. The annualized rates of heart failure hospitalization were 35.8% per patient-year in the device group versus 67.9% per patient-year in the control group (HR 0.53, 95% CI [0.40 to 0.70]; p<0.001). In addition, the 12-month freedom from device-related complications was 96.6% [lower 95% confidence limit, 94.8%], which exceeded the performance goal of 88.0% for the primary safety endpoint (p<0.001). All-cause mortality at 24 months with the device was 29.1% compared to 46.1% in the control group (HR 0.62, 95% CI [0.46 to 0.82]; p<0.001).

In addition to the reductions in hospitalizations and mortality, device treatment also resulted in improvements in quality-of-life measures and functional capacity. The study found a mean 12.5-point increase in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score from baseline to 12 months after transcatheter mitral repair compared to a mean 3.6-point reduction in the control group. Similarly, exercise capacity as measured by six-minute walk distance (6MWD) decreased during 12-month follow-up by nearly 60 meters with GDMT alone but remained unchanged after transcatheter mitral repair. Heart failure classification (NYHA functional class) was also improved to a greater degree with the transcatheter device compared with GDMT alone at all follow-up times. Patients treated with the MitraClip also had a lower incidence of heart transplant or a left ventricular assist device (LVAD) (4.4% for the device group versus 9.5% for the control group).

"At two years, transcatheter mitral valve repair with the MitraClip device was found to be safe and effective. It substantially reduced the rate of hospitalizations and mortality, while improving quality-of-life and functional capacity," added Dr. Stone. "This procedure gives cardiologists an important option for high-risk heart failure patients with secondary MR who remain symptomatic despite optimal medical therapy."

###

The COAPT trial was funded by Abbott Vascular. Dr. Stone reported consulting fees from Neovasc, Valfix, and Gore, as well as equity/options in Ancora. He also reported that his employer, Columbia University, receives royalties from Abbott for sale of the MitraClip.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and educated doctors on the latest treatments for heart disease.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. Now in its 30th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field. TCT also includes interactive training where clinicians can gain vital skills to apply immediately to their practices.

For more information, visit http://www.crf.org and http://www.tctconference.com.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.